肿瘤防治研究2024，Vol.51Issue(7)：535-541,7.DOI:10.3971/j.issn.1000-8578.2024.24.0116
Dato-DXd治疗晚期非小细胞肺癌新进展
New Advances in Dato-DXd Treatment for Advanced Non-Small-Cell Lung Cancer
摘要
Abstract
Approximately 50%of patients with non-small-cell lung cancer(NSCLC)are diagnosed at advanced stages and face a challenging prognosis despite the integration of targeted therapies,immun-otherapy,and systemic chemotherapy into current standard care.A key factor in this context is trophoblast cell-surface antigen 2(TROP2),which is widely expressed in NSCLC and strongly associated with poor patient outcomes.This article examines the latest developments in the application of datopotamab deruxtecan(Dato-DXd,DS-1062),a novel antibody-drug conjugate targeting TROP2,in the treatment of NSCLC.It provides a detailed assessment of Dato-DXd's technical design,evaluates its efficacy by using recent clinical trial data,and discusses its safety profile.关键词
非小细胞肺癌/抗体偶联药物/人滋养层细胞表面抗原2/Dato-DXdKey words
Non-small-cell lung cancer/Antibody-drug conjugate/TROP2/Dato-DXd分类
医药卫生引用本文复制引用
陈露露,宋启斌..Dato-DXd治疗晚期非小细胞肺癌新进展[J].肿瘤防治研究,2024,51(7):535-541,7.基金项目
National Natural Science Foundation of China(Nos.82102841,82273094) 国家自然科学基金(82102841,82273094) （Nos.82102841,82273094）
